Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Détails bibliographiques
Publié dans:Clinical immunology (Orlando, Fla.). - 1999. - 218(2020) vom: 01. Sept., Seite 108517
Auteur principal: Yeleswaram, Swamy (Auteur)
Autres auteurs: Smith, Paul, Burn, Timothy, Covington, Maryanne, Juvekar, Ashish, Li, Yanlong, Squier, Peg, Langmuir, Peter
Format: Article en ligne
Langue:English
Publié: 2020
Accès à la collection:Clinical immunology (Orlando, Fla.)
Sujets:Journal Article Research Support, Non-U.S. Gov't Review COVID-19 Coronavirus Cytokine storm Janus kinase Ruxolitinib Anti-Inflammatory Agents Cytokines plus... Nitriles Protein Kinase Inhibitors Pyrazoles Pyrimidines ruxolitinib 82S8X8XX8H JAK1 protein, human EC 2.7.10.2 JAK2 protein, human Janus Kinase 1 Janus Kinase 2